Beta-blockers in elderly patients: neuroprotective effect or risk of cognitive decline?

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: Due to the fact that the number of elderly people with cognitive disorders is steadily increasing worldwide, there is an increased interest in studying the effects of drugs of different pharmacological groups on cognitive function.

For many years, beta-blockers have been one of the main groups in the therapy of cardiovascular diseases. The effect of beta-blockers on cognitive function has been studied for a long time, and there is different, sometimes contradictory data on this issue.

AIM: To evaluate the incidence of cognitive impairment in elderly and to determine the associations between cognitive impairment and the beta-blockers use.

MATERIALS AND METHODS: Cross-sectional study included all patients aged 60 years and older who attended the ambulance care from 24.10.2019 to 15.12.2019 at the polyclinic No. 78 in Saint Petersburg.

Measurements: the Montreal cognitive assessment (MoCA) test, the 15-item Geriatric Depression Scale. Data collection included a full medical history, a medication review and questionnaire.

RESULTS: The prevalence of cognitive impairment among the study participants was 71.1% (n = 138). Сognitive impairment was associated with high blood pressure and a history of stroke (p < 0.05). Beta-blockers use was associated with decreased in total MoCA score, fluency (p = 0.0115), thinking (p = 0.0012), and memory (p = 0.0040). The identified association remained statistically significant after adjusting for gender, age, high blood pressure, a history of stroke, level of education, and decreased emotional background with odds ratio 2.245 (95% confidence interval 1.156–4.358) for the fluency test and coefficient of regression −0.781 (95% confidence interval [−1,233]–[−0,328]) for delayed memory.

CONCLUSIONS: Memory impairment (coefficient of regression −0.781, 95% confidence interval −1.233 to −0.328) and decreased fluency (odds ratio 2.245; 95% confidence interval 1.156–4.358) were observed in the study in the outpatient elderly patient population taking beta-blockers. The beta-blockers may lead to memory impairment. When choosing hypotensive therapy, all possible effects of beta-blockers should be considered, including the effect on cognitive status.

About the authors

Tatyana A. Bogdanova

North-Western State Medical University named after I.I. Mechnikov

Author for correspondence.
Email: bogdanova.t@szgmu.ru
ORCID iD: 0000-0002-8636-8003
SPIN-code: 4126-6041
Russian Federation, Saint Petersburg

Anna V. Turusheva

North-Western State Medical University named after I.I. Mechnikov

Email: anna.turusheva@gmail.com
ORCID iD: 0000-0003-3347-0984
SPIN-code: 9658-8074
Scopus Author ID: 57189466350
ResearcherId: U-3654-2017

MD, Cand. Sci. (Med.), Assistant Professor

Russian Federation, Saint Petersburg

References

  1. Pharmacotherapy in the elderly and senile: methodological guidelines. Available from: https://rgnkc.ru/images/metod_materials/Farmakoterapiya_2018.pdf. Accessed: June 15, 2022. (In Russ.)
  2. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699. doi: 10.1111/j.1532-5415.2005.53221.x
  3. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17(1):37–49. doi: 10.1016/0022-3956(82)90033-4
  4. Sierra C. Hypertension and the risk of dementia. Front Cardiovasc Med. 2020;7:5. doi: 10.3389/fcvm.2020.00005
  5. Gelber RP, Ross GW, Petrovitch H, et al. Antihypertensive medication use and risk of cognitive impairment: the Honolulu-Asia Aging Study. Neurology. 2013;81(10):888–895. doi: 10.1212/WNL.0b013e3182a351d4
  6. Moretti R, Torre P, Antonello RM, et al. Risk factors for vascular dementia: hypotension as a key point. Vasc Health Risk Manag. 2008;4(2):395–402. doi: 10.2147/vhrm.s2434
  7. Sara SJ. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci. 2009;10(3):211–223. doi: 10.1038/nrn2573
  8. Paredes DA, Cartford MC, Catlow BJ, et al. Neurotransmitter release during delay eyeblink classical conditioning: role of norepinephrine in consolidation and effect of age. Neurobiol Learn Mem. 2009;92(3):267–282. doi: 10.1016/j.nlm.2008.08.008
  9. Arrieta-Cruz I, Wang J, Pavlides C, Pasinetti GM. Carvedilol reestablishes long-term potentiation in a mouse model of Alzheimer’s disease. J Alzheimers Dis. 2010;21(2):649–654. doi: 10.3233/JAD-2010-100225
  10. Wang J, Ono K, Dickstein DL, et al. Carvedilol as a potential novel agent for the treatment of Alzheimer’s disease. Neurobiol Aging. 2011;32(12):2321.e1–12. doi: 10.1016/j.neurobiolaging.2010.05.004
  11. Beaman EE, Bonde AN, Ulv Larsen SM, et al. Blood-brain barrier permeable β-blockers linked to lower risk of Alzheimer’s disease in hypertension. Brain. 2022;awac076. doi: 10.1093/brain/awac076
  12. Nevado-Holgado AJ, Kim CH, Winchester L, et al. Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. BMJ Open. 2016;6(11):e012177. doi: 10.1136/bmjopen-2016-012177
  13. Burkauskas J, Noreikaite A, Bunevicius A, et al. Beta-1-selective Beta-blockers and cognitive functions in patients with coronary artery disease: a cross-sectional study. J Neuropsychiatry Clin Neurosci. 2016;28(2):143–146. doi: 10.1176/appi.neuropsych.15040088
  14. Holm H, Ricci F, Di Martino G, et al. Beta-blocker therapy and risk of vascular dementia: a population-based prospective study. Vascul Pharmacol. 2020;125–126:106649. doi: 10.1016/j.vph.2020.106649
  15. Lobzin VYu, Emelin AYu. Depression and dementia: differentiation and comorbidity. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):100–106. (In Russ.). doi: 10.14412/2074-2711-2020-4-100-106
  16. Kessing LV, Rytgaard HC, Ekstrøm CT, et al. Antihypertensive drugs and risk of depression: a nationwide population-based study. Hypertension. 2020;76(4):1263–1279. doi: 10.1161/HYPERTENSIONAHA.120.15605
  17. Vorobyeva OV, Pilipovich AA, Fateeva VV. Impact of endothelial inflammation on depression in patients with cerebral microangiopathy: a prospective study. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(1):32–37. (In Russ.). doi: 10.14412/2074-2711-2022-1-32-37
  18. Silva IVG, de Figueiredo RC, Rios DRA. Effect of different classes of antihypertensive drugs on endothelial function and inflammation. Int J Mol Sci. 2019;20(14):3458. doi: 10.3390/ijms20143458

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bogdanova T.A., Turusheva A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).